Approval Of Novartis' Everolimus Could Mean mTOR Inhibitor Class REMS
Executive Summary
The likely approval of Novartis' everolimus for prevention of kidney transplant rejection could bring with it safety labeling updates and Risk Evaluation and Mitigation Strategies for all drugs in the mTOR inhibitor class
You may also be interested in...
Imposing Everolimus REMS On Sirolimus Rests On If There Is New Safety Info
The approval of Novartis' Zortress (everolimus) with a Risk Evaluation and Mitigation Strategy has opened up an FDA review of whether Pfizer's Rapamune (sirolimus), from which everolimus is derived, should have a similar plan
Imposing Everolimus REMS On Sirolimus Rests On If There Is New Safety Info
The approval of Novartis' Zortress (everolimus) with a Risk Evaluation and Mitigation Strategy has opened up an FDA review of whether Pfizer's Rapamune (sirolimus), from which everolimus is derived, should have a similar plan
Panel Recommends Novartis' Kidney Transplant Drug Certican
Taking the panel's previous advice to demonstrate everolimus' efficacy with lower doses of cyclosporine is what gained the committee endorsement Dec. 7.